rawfin.tv
Tempest Therapeutics Narrows Q2 Loss to $5.2 Million, Advances CAR-T Pipeline
EarningsstocksAI Generated

Tempest Therapeutics Narrows Q2 Loss to $5.2 Million, Advances CAR-T Pipeline

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Tempest Therapeutics reported a Q2 net loss of $5.2 million, a significant improvement from the previous year, indicating progress in cost management. The biotechnology firm also highlighted advancements in its CAR-T pipeline, signaling potential future growth in its therapeutic development.

TPSTEarnings reportBiotechnologyCAR-TPharmaceutical pipeline

Related Articles

China Equities Lag US Stocks by Record 2.095 Valuation Ratio

China Equities Lag US Stocks by Record 2.095 Valuation Ratio

stocks
S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

stocks
Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

stocks
Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

stocks